Alexandra Charrow, MD
Dermatology · Boston, MANPI 1679986830
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $22,068 of the $23,891 with a category attached, or 92.4%. 3 manufacturers reported payments, led by Incyte Corporation at 39.3% of the total. Among dermatology clinicians in MA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 20 payments — averaging $1194.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Incyte Corporation$9K
- Novartis$9K
- UCB, Inc.$6K
Across 168 payments — averaging $622.82 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Incyte Corporation$105K
What the payments were for
- Consulting fees$22,06892%
- Travel & lodging$1,3025%
- Food & beverage$5222%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Incyte Corporation | 9 | $9,394 |
| Novartis | 5 | $8,900 |
| UCB, Inc. | 6 | $5,597 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$23,891 in reported general payments places this provider in the 90th percentile of 552 dermatology providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Cosentyx Sensoready (2 Pens)Secukinumab | 98 | $1,035,153 |
| Humira(Cf) PenAdalimumab | 28 | $601,344 |
| RinvoqUpadacitinib | 41 | $351,653 |
| OtezlaApremilast | 47 | $220,567 |
| Dupixent SyringeDupilumab | 32 | $144,780 |
| Dupixent PenDupilumab | 30 | $108,236 |
| Clobetasol Propionate | 41 | $3,481 |
| Betamethasone Diprop AugmentedBetamethasone/Propylene Glyc | 48 | $2,818 |
| Tacrolimus | 15 | $2,000 |
| Fluorouracil | 26 | $1,783 |
| Doxycycline Monohydrate | 67 | $1,634 |
| Doxycycline Hyclate | 17 | $1,632 |
| Metronidazole | 33 | $1,503 |
| Clindamycin Phosphate | 33 | $1,002 |
| Betamethasone Dipropionate | 11 | $917 |
Paid to pharmacies, not to this prescriber.
Other dermatology in Boston
- Alexandra KimballBoston$680K
- Arash MostaghimiBoston$591K
- Brian HiblerBoston$498K
- Maryanne SennaBoston$430K
- Ruth Ann VleugelsBoston$368K
- Gabriela CobosBoston$343K
- Martina PorterBoston$220K
- Mathew AvramBoston$209K
- Emmy GraberBoston$159K
- Neelam VashiBoston$156K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.